What was studied?
Two randomized, double-blind, placebo-controlled dose-escalation studies followed healthy adults for 28 or 49 days. Investigators measured circulating CJC-1295, growth hormone and IGF-I rather than disease recovery or functional performance.
What did the researchers report?
The long-acting analogue produced sustained increases in growth hormone and IGF-I. Repeated exposure showed accumulation in the measured hormonal response. The investigators reported no serious adverse reactions in these short studies.
What are the limits?
These findings concern a long-acting, albumin-binding analogue, not a no-DAC material or an ipamorelin blend. Short-term tolerability in selected adults cannot establish long-term safety, effectiveness for a disease, or equivalence of commercial research materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.